首页 > 市场调查报告书 > 製药

临床实验

市场调查报告书

商品编码

1707474

全球口咽念珠菌念珠菌症市场按类型、治疗、给药途径、分销管道和地区划分

Global Oropharyngeal Candidiasis Market, By Type, By Treatment, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2025年03月04日 | 出版商:

Coherent Market Insights | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年全球口咽念珠菌症市场规模估计为 4.564 亿美元，预计到 2032 年将达到 6.128 亿美元，2025 年至 2032 年的复合年增长率为 4.3%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	4.564亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	4.30%	2032年价值预测	6.128亿美元

数字。 2025年全球口咽念珠菌症各地区全球市场占有率（%）

口咽念珠菌症（OPC），通常也称为鹅口疮，是由口腔和喉咙黏膜中念珠菌属（主要是白色念珠菌）过度生长引起的真菌感染疾病。念珠菌是口腔微生物群的正常组成部分，但在某些条件下，微生物的微妙平衡会被打破，导致念珠菌过度生长。它在免疫系统较弱的人群中更为常见，例如患有人类免疫力缺乏病毒/后天免疫力缺乏症候群（爱滋病毒/爱滋病）的人、正在接受化疗的人和服用广谱抗生素的人。糖尿病患者、服用皮质类固醇的人和戴假牙的人也可能出现这种情况。感染疾病的典型特征是舌头、脸颊内侧、口腔顶部、牙龈、扁桃体和喉咙后部出现白斑。这些病灶可能会略微凸起，在严重的情况下，可能会导致不适或吞嚥困难。念珠菌症是一种在免疫力缺乏的人群中广泛传播的疾病，引起了医学研究和患者照护的广泛关注。念珠菌是口腔菌丛的正常组成部分，对大多数人无害，但免疫力缺乏、长期使用抗生素、糖尿病和某些医疗等各种情况都可能使人容易罹患这种机会性真菌感染疾病。这种感染疾病的特征性症状是口腔和喉咙黏膜表面出现乳白色病变。这些病变可能会让人感到不舒服，如果病灶范围较大，可能会影响正常进食和吞嚥。 OPC 的治疗通常涉及抗真菌药物，并专注于解决可能导致真菌过度生长的任何潜在疾病。市场分析显示，该疾病治疗领域受到全球糖尿病和爱滋病毒/爱滋病高发病率的严重影响，导致对有效抗真菌疗法的需求增加。

市场动态：

全球口咽念珠菌症市场受到爱滋病毒/爱滋病盛行率上升以及更容易受到真菌感染疾病的老年人口增加的推动。此外，日益激进的肿瘤导向治疗以及频谱抗生素和皮质类固醇治疗的频繁使用加剧了鹅口疮的风险。然而，市场可能面临学名药竞争加剧和替代治疗方案可用性等限制因素。

本研究的主要特点

本报告对全球口咽念珠菌症市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和复合年增长率。
它还强调了各个领域的潜在商机，并说明了该市场的引人注目的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数列出了全球口咽念珠菌症市场的主要企业简介。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴车型、市场扩张和行销策略做出明智的决策。
全球口咽念珠菌念珠菌症市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员将透过用于分析全球口咽念珠菌症市场的各种策略矩阵更轻鬆地做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 456.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	4.30%	2032 Value Projection:	USD 612.8 Mn

Oropharyngeal candidiasis (OPC) which is also commonly known as oral thrush, is a fungal infection which is caused by the overgrowth of Candida species, predominantly Candida albicans, in the oral and pharyngeal mucous membranes. While Candida is a normal component of the oral microbiota, certain conditions can disrupt the delicate balance of microorganisms, thereby leading to its excessive proliferation. It is frequently observed in individuals with compromised immune systems, such as those with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), undergoing chemotherapy, or taking broad-spectrum antibiotics. It can also occur in patients with diabetes or those who use corticosteroids or wear dentures. The infection is typically characterized by white patches on the tongue, inner cheeks, and roof of the mouth, gums, tonsils, or the back of the throat. These lesions can be slightly raised and may cause discomfort or difficulty in swallowing when severe. It is a condition that has garnered significant attention within medical research and patient care due to its pervasive nature in immunocompromised populations. While Candida is a standard tenant of the oral flora among many individuals without causing harm, various circumstances, such as immunodeficiency, extended antibiotic use, diabetes, and certain medical therapies, can predispose individuals to this opportunistic fungal infection. The hallmark symptoms of this infection consist of creamy white lesions that appear on the mucosal surfaces of the oral cavity and the throat. These lesions are sometimes accompanied by discomfort and can impede proper nutrition and swallowing when they are extensive. The treatment landscape for OPC typically involves antifungal medications, with an emphasis on addressing any underlying conditions that may have led to the fungal overgrowth. Market analysis reveals that the therapeutic area for this condition is significantly influenced by the high prevalence of diabetes and HIV/AIDS globally, with a resultant increase in demand for efficacious antifungal therapies.

Market Dynamics:

Global oropharyngeal candidiasis market is driven by the rising prevalence of HIV/AIDS along with a growing elderly population that is susceptible to fungal infections. Moreover, increasingly aggressive tumor-directed therapies along with frequent use of broad-spectrum antibiotic and corticosteroid therapies spur the risk of oral thrush. However, the market potentially faces restraints from rising generics competition and availability of alternate treatment options.

Key features of the study:

This report provides in-depth analysis of the global oropharyngeal candidiasis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global oropharyngeal candidiasis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer, Wockhardt, Ranbaxy Laboratories, Bristol Laboratories, Glenmark Pharmaceuticals Ltd, and GlaxoSmithKline.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global oropharyngeal candidiasis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oropharyngeal candidiasis market.

Detailed Segmentation:

Global Oropharyngeal Candidiasis Market, By Type
- Pseudomembranous
- Erythematous
- Hyperplastic
Global Oropharyngeal Candidiasis Market, By Treatment
- Anti-fungal
- Immune-modulators
Global Oropharyngeal Candidiasis Market, By Route of Administration
- Oral
- Topical
- Others
Global Oropharyngeal Candidiasis Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Oropharyngeal Candidiasis Market, By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Bayer AG
- Teva Pharmaceuticals
- Stellar Pharma
- Pfizer
- Wockhardt
- Ranbaxy Laboratories
- Bristol Laboratories
- Glenmark Pharmaceuticals Ltd
- GlaxoSmithKline

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Oropharyngeal Candidiasis, By Type
- Market Oropharyngeal Candidiasis, By Treatment
- Market Oropharyngeal Candidiasis, By Route of Administration
- Market Oropharyngeal Candidiasis, By Distribution Channel
- Market Oropharyngeal Candidiasis, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
Increasing prevalence of HIV/AIDS
Rising research funding and projects
Increasing number of healthcare facilities
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations

4. Global Oropharyngeal Candidiasis Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Oropharyngeal Candidiasis Market, By Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pseudomembranous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Erythematous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Hyperplastic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Oropharyngeal Candidiasis Market, By Treatment, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Anti-fungal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Immune-modulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Oropharyngeal Candidiasis Market, By Route of Administration, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Oropharyngeal Candidiasis Market, By Distribution Channel, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

9. Global Oropharyngeal Candidiasis Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2020 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032 ,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Company Profile
- Bayer AG
Company Highlights
Type Portfolio
Key Developments
Financial Performance
Strategies
- Teva Pharmaceuticals
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Stellar Pharma
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Pfizer
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Wockhardt
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Ranbaxy Laboratories
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Bristol Laboratories
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Glenmark Pharmaceutical Ltd
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- GlaxoSmithKline
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

11. Section

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

全球口咽念珠菌念珠菌症市场按类型、治疗、给药途径、分销管道和地区划分